Vaxil Bio Ltd.

TSXV:VXL Canada Healthcare — Biotechnology

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has complet…

Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the full company research view.
Results 2026-05-28
Open PDF
Interim MD&A - English.pdf
Results 2026-05-28
Open PDF
Interim financial statements/report – English.pdf
Results 2026-05-01
Open PDF
Annual MD&A - English.pdf
Results 2026-05-01
Open PDF
Audited annual financial statements – English.pdf
News 2025-12-16
Report of exempt distribution (45-106F1).pdf
Transactions 2025-12-04 Financing
Open PDF
Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors
News release - English.pdf
Results 2025-11-27 Financials
Open PDF
Interim financial statements/report – English.pdf
Results 2025-11-27 Financials
Open PDF
Interim MD&A - English.pdf
Transactions 2025-11-24 Financing
Open PDF
Vaxil Announces Update on Non-Brokered Private Placement
News release - English.pdf
News 2025-10-29
Open PDF
News release - English.pdf
Results 2025-08-29 Financials
Open PDF
Interim MD&A - English.pdf
Results 2025-08-29 Financials
Open PDF
Interim financial statements/report – English.pdf

Showing 12 of 22 items in this period.